Which Capping and Lamination Mechanisms Appear When Calcium Levulinate Dihydrate Is Compressed Above 68% w/w?

In direct compression tablet manufacturing, calcium levulinate dihydrate is typically incorporated at 76.4% w/w to deliver 100 mg elemental calcium per unit, corresponding to 764.5 mg of the dihydrate salt per tablet based on the calcium content of 13.08% w/w. This addition ratio is calculated from the molecular weight of the dihydrate, 306.3 g/mol, and the stoichiometric factor of 7.645 g calcium levulinate dihydrate per 1 g elemental calcium. On rotary tablet presses equipped with D-tooling, the blend containing the API, microcrystalline cellulose, crospovidone, and magnesium stearate at 0.5–1.0% w/w is compressed at a main compression force of 12–25 kN, with precompression force set at 5–10 kN and turret speed limited to 20–50 rpm. At API loads above 68% w/w, capping and lamination have been observed when the residual moisture of the blend is below 1.5% w/w or when magnesium stearate total blend time exceeds 5 min; the resulting tablets are checked for friability under USP <1216> at a limit of not more than 1.0% and for calcium assay by complexometric titration after acid dissolution. Compliance for content uniformity uses USP <905> or Ph. Eur. 2.9.40, while dissolution release in 0.1 M hydrochloric acid is evaluated using USP <711> or Ph. Eur. 2.9.3 with apparatus II at 50 rpm. Elemental impurity control follows ICH Q3D with inductively coupled plasma–mass spectrometry per USP <233>. Terminal finished product types are uncoated flat-faced or caplet-shaped tablets containing 50 mg to 200 mg elemental calcium per unit, intended for oral administration as single-ingredient calcium supplementation or in fixed-dose combinations with vitamin D₃.

When high-speed capsule fillers are set to dosator nozzle speeds above 60 cycles/min, powder blends containing calcium levulinate dihydrate and pregelatinised starch have shown segregation-induced weight variability unless the blend is pre-moistened and dried to a loss-on-drying range of 1.8–2.5% w/w. The API is typically incorporated at 65–75% w/w in a size 00 hard gelatin or HPMC capsule formulation delivering 100 mg elemental calcium per capsule from 764.5 mg of calcium levulinate dihydrate. Dry granulation with low-substituted hydroxypropyl cellulose is employed prior to encapsulation when the API exhibits flow function coefficient below 4; granule bulk density is held between 0.55–0.65 g/mL, and fill weight control is monitored at ±3% relative standard deviation using USP <905> or Ph. Eur. 2.9.40. Disintegration time is tested according to USP <701> with a limit of not more than 15 minutes in water at 37 °C, and dissolution release is evaluated by USP <711> in 0.1 M hydrochloric acid. Terminal finished product types include hard gelatin capsules and vegetarian HPMC capsules in strengths of 50 mg, 100 mg, and 150 mg elemental calcium, often combined with cholecalciferol or menaquinone in osteoporosis support formulations.

When Effervescent Granule Manufacturing Must Harmonise Acid–Base Molar Control With Calcium Levulinate Addition

Effervescent formulations containing calcium levulinate dihydrate are processed by wet granulation of anhydrous citric acid and sodium bicarbonate, with the API incorporated in a dry powder mix after the effervescent couple has been granulated and dried below 2.0% w/w residual moisture. For a single-dose sachet delivering 200 mg elemental calcium, the addition ratio is 1.529 g calcium levulinate dihydrate per unit dose. The granulate is dried in a fluid-bed dryer with inlet air at 45–55 °C until the loss-on-drying is 1.0–2.0% w/w; terminal blending passes through a 1.0 mm sieve to reduce segregation. In-use disintegration of the final oral solution is observed with complete dissolution in 150 mL water at 20 °C within 120 seconds, and the solution is assessed for clarity and pH between 4.5–5.5. Packaging in sachets requires aluminium foil laminate with water vapour transmission rate below 0.1 g/m²/day to protect the acid–base couple. Compliance for related substances and stability follows ICH Q1A(R2); elemental impurities are controlled per ICH Q3D with inductively coupled plasma–mass spectrometry according to USP <233>. Terminal finished product types are single-dose stick packs or sachets producing a clear or slightly opalescent lemon-flavoured solution containing 100 mg to 250 mg elemental calcium per dose.

Terminally sterilised aqueous solutions of calcium levulinate dihydrate intended for intravenous or intramuscular administration are compounded at 10% w/v of the dihydrate salt, equivalent to 13.08 mg/mL elemental calcium, and filled into 5 mL or 10 mL Type I borosilicate glass ampoules or vials under nitrogen blanketing. The solution is prepared in water for injection at 20–25 °C, the pH is adjusted to 6.0–7.0 with dilute levulinic acid or sodium hydroxide, and the solution is filtered through a 0.22 µm sterilising-grade filter before terminal autoclaving at 121 °C for 15 minutes. Manufacturing compliance is governed by EU GMP Annex 1 for sterile products, USP <71> or Ph. Eur. 2.6.1 for sterility, USP <85> or Ph. Eur. 2.6.14 for bacterial endotoxins, and USP <788> or Ph. Eur. 2.9.19 for sub-visible particulate matter. Incompatibility with phosphate-containing intravenous fluids must be assessed prior to admixture because calcium ion concentration above 20 mEq/L combined with phosphate can precipitate calcium phosphate; published data for this specific configuration is limited. Terminal finished product types are ampoules or vials for intravenous infusion after dilution in sodium chloride or glucose infusion fluids, and intramuscular injection products labelled for correction of hypocalcaemia.

Oral Drops and Syrups: Preservative Partitioning, Buffer Capacity, and Fill-Temperature Control

Oral liquid dosage forms of calcium levulinate dihydrate are prepared by dissolving the API at 10% w/v in purified water containing sodium benzoate at 0.15% w/v or potassium sorbate at 0.2% w/v, followed by pH adjustment to 5.0–6.5 with citric acid. Each 5 mL dose delivers 65.4 mg elemental calcium when formulated at 10% w/v of the dihydrate; this addition ratio is adjusted for paediatric drops to 5% w/v delivering 6.54 mg/mL elemental calcium. The bulk solution is mixed under vacuum at 20–25 °C and held for 8–12 hours to allow complete dissolution, filtered through a 0.45 µm polypropylene filter, and filled by volumetric piston pumps into amber Type III glass bottles of 15 mL, 30 mL, or 100 mL with child-resistant closures. Stability-indicating methods for assay and related substances follow ICH Q1A(R2) photostability and thermal cycling conditions; microbial quality acceptance uses Ph. Eur. 5.1.3 or USP <1111> categories for non-sterile liquids. Terminal finished product types are unflavoured oral solutions, paediatric drops, and elder-care syrups for calcium supplementation.

For multidose bottles delivering a spoonable oral suspension, the roller compaction route is selected when calcium levulinate dihydrate must be delivered as a dispersible powder because the crystalline API alone exhibits poor flow and segregation at fill weights above 1.5 g. At a final blend ratio of 50–60% w/w calcium levulinate dihydrate, a roller compactor with ribbed rolls at 30–50 bar hydraulic pressure is used to densify the material; the ribbons are milled through a 1.0 mm screen to produce granules with bulk density 0.60–0.72 g/mL. The granules are filled into 100 g or 200 g HDPE bottles with a spoon dosing system calibrated to deliver 250 mg elemental calcium per 1.91 g scoop. The suspension prepared by dispersing the granules in 30 mL water is assessed for sedimentation volume and resuspendability, while drug release from the reconstituted suspension is tested using USP <711> apparatus II with paddle speed 50 rpm in 0.1 M hydrochloric acid. Compliance for the dry granulation process includes batch uniformity verification by USP <905> and residual moisture control below 2.5% w/w. Terminal finished product types are multidose powder for oral suspension and unit-dose dispersible sachets.